bioRxivCancer Biology
KSR2 promotes self-renewal and clonogenicity of small-cell lung carcinoma
D. H. Huisman, D. Chatterjee, R. A. Svoboda, H. M. Vieira, A. S. Ireland, S. Skupa, J. W. Askew, D. E. Frodyma, L. Girard, K. W. Fisher, M. Kareta, J. Minna, T. G. Oliver, R. E. Lewis
Abstract
Small-cell lung carcinoma (SCLC) tumors are heterogeneous, with a subpopulation of cells primed for tumor initiation. Here, we show that Kinase Suppressor of Ras 2 (KSR2) promotes the self-renewal and clonogenicity of SCLC cells. KSR2 is a molecular scaffold that promotes Raf/MEK/ERK signaling. KSR2 is preferentially expressed in the ASCL1 subtype of SCLC (SCLC-A) tumors and is expressed in pulmonary neuroendocrine cells, one of the identified cells of origin for SCLC-A tumors. The expression of KSR2 in SCLC and pulmonary neuroendocrine cells (PNECs) was previously unrecognized and serves as a novel model for understanding the role of KSR2-dependent signaling in normal and malignant tissues. Disruption of KSR2 in SCLC-A cell lines inhibits the colony forming ability of tumor propagating cells (TPCs) in vitro and their tumor initiating capacity in vivo. The effect of KSR2 depletion on self-renewal and clonogenicity is dependent on the interaction of KSR2 with ERK. These data indicate that the expression of KSR2 is an essential driver of SCLC-A tumor propagating cell function, and therefore may play a role in SCLC tumor initiation. These findings shed light on a novel effector promoting initiation of ASCL1-subtype SCLC tumors, and a potential subtype-specific therapeutic target. ImplicationsManipulation of the molecular scaffold KSR2 in ASCL1-subtype small-cell lung cancer cells reveals its contribution to self-renewal, clonogenicity, and tumor initiation.
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- KSR1 mediates small-cell lung carcinoma tumor initiation and cisplatin resistance
Deepan Chatterjee, Robert A. Svoboda, … Robert E. Lewis·Molecular Cancer ResearchPeer-reviewed·Feb 10, 2025
- Distinct transcriptional programs of SOX2 in different types of small cell lung cancers
Y. Tenjin, K. Matsuura, … T. Ito·bioRxiv·Nov 28, 2019
- ASCL1-ERK1/2 Axis: ASCL1 restrains ERK1/2 via the dual specificity phosphatase DUSP6 to promote survival of a subset of neuroendocrine lung cancers
A. Martin-Vega, S. Earnest, … M. H. Cobb·bioRxiv·Jun 15, 2023
- ASCL1 represses a latent osteogenic program in small cell lung cancer in multiple cells of origin
R. R. Olsen, D. W. Kastner, … T. G. Oliver·bioRxiv·Nov 11, 2020
- Transcriptional circuitry of NKX2-1 and SOX1 defines an unrecognized lineage subtype of small cell lung cancer
Ranran Kong, Ayushi S. Patel, … Hideo Watanabe·American Journal of Respiratory and Critical Care MedicinePeer-reviewed·Jul 18, 2022
- Sox2 is an oncogenic driver of small cell lung cancer
E. Voigt, H. Wollenzien, … M. Kareta·bioRxiv·Jun 3, 2019